Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
5 clusters · 10 sources · 36 days · First seen · Last updated
Atrial fibrillation stroke prevention and cognitive research
Overview
Clinical research has increasingly supported the use of oral anticoagulants (OAC) for stroke prevention in patients with atrial fibrillation (AF) at intermediate risk.
Data from the SINGLE-AF trial, published in The New England Journal of Medicine, indicates that direct oral anticoagulants (DOAC) can reduce serious clinical events. Led by Professor Boyoung Joung at Yonsei University, the study followed 1,803 participants across 18 medical centers in South Korea for two years. While high-risk patients are routinely prescribed blood thinners and low-risk patients often are not, the benefits for intermediate-risk patients have previously lacked randomized trial data. The findings, presented at ESC Congress 2026, showed that the primary outcome—a combination of stroke, systemic embolism, major hemorrhage, or cardiovascular death—occurred in 0.5% of the treated group compared to 1.5% in the untreated group, representing a relative risk reduction of approximately 69%. Stroke frequency was also lower in the treated group, with three cases compared to ten in the control group.
A meta-analysis in JAMA Cardiology suggested that transcatheter left atrial appendage closure (LAAC) should not be a routine first-line alternative to OAC, as it was associated with a 34% higher risk of ischemic stroke compared to anticoagulation.
Recent research from the Karolinska Institutet in Sweden, published in the European Heart Journal, suggests potential cognitive benefits for patients with both Alzheimer’s disease and atrial fibrillation. Analyzing data from 7,308 individuals via Sweden’s national dementia registry, the study found that patients using newer non-vitamin K oral anticoagulants (NOACs) experienced a slower decline in Mini-Mental State Examination (MMSE) scores—approximately 0.21 to 0.23 points per year—compared to those using warfarin or no anticoagulants. Professor Maria Eriksdotter noted that the effect might be due to ‘improved blood flow and reduced small-scale brain damage’ and could become more significant over longer periods.
Entities
New England Journal of Medicine · European Society of Cardiology · Severance Cardiovascular Hospital · SveDem · Yonsei University
Timeline
-
[HEALTH] 2 sourcesOral anticoagulants studied for intermediate stroke risk in atrial fibrillation
The SINGLE-AF trial studied whether oral anticoagulants like apixaban and rivaroxaban reduce stroke risk in intermediate-risk atrial fibrillation patients.
-
[HEALTH] 2 sourcesAnticoagulants reduce stroke risk in atrial fibrillation patients
The SINGLE-AF trial in South Korea found that direct oral anticoagulants reduce the risk of stroke and major clinical events by approximately 69% in patients with intermediate-risk atrial fibrillation.
-
[HEALTH] 3 sourcesNew blood thinners linked to slower cognitive decline in Alzheimer’s patients
A Swedish study suggests newer blood thinners (NOACs) may slow cognitive decline in Alzheimer’s patients who also have atrial fibrillation compared to those using warfarin or no anticoagulants.
-
[HEALTH] 2 sourcesSeverance Hospital study finds anticoagulants reduce stroke risk in atrial fibrillation patients
A clinical study from Severance Cardiovascular Hospital shows that anticoagulants reduce stroke and embolism risks by up to 90% in atrial fibrillation patients with intermediate risk levels.
-
[HEALTH] 2 sourcesOral anticoagulants reduce stroke risk in atrial fibrillation patients
Clinical studies confirm that oral anticoagulants effectively reduce stroke and mortality risk in intermediate-risk atrial fibrillation patients, while LAAC is not recommended as a first-line alternative.
Sources
consultantlive.com · diariodesalud.com.do · hin.company · immedicohospitalario.es · knowridge.com · medicaldialogues.in · sciencedaily.com · thebionews.net · timesnownews.com · world-today-news.com
This summary has been updated 3 times: see revision history